Multiplex Ligation-dependent Probe Amplification Can Clarify HER2 Status in Gastric Cancers with “Polysomy 17”

Therapy with trastuzumab confers a survival benefit in HER2 positive advanced gastric and gastroesophageal adenocarcinoma. HER2 status is evaluated by immunohistochemistry (IHC) and in situ hybridization (ISH). An ISH ratio of HER2 to centromere 17 (CEP17) ≥2.0 is considered amplified. This assumes...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Cancer
Autors principals: Wang, Tao, Amemiya, Yutaka, Henry, Pauline, Seth, Arun, Hanna, Wedad, Hsieh, Eugene T.
Format: Artigo
Idioma:Inglês
Publicat: Ivyspring International Publisher 2015
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4392047/
https://ncbi.nlm.nih.gov/pubmed/25874002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.11424
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars